Total number of problems addressed per participant at each step in each site.

<p>Bold text indicates roll-out of medicines’ monitoring and Profile administration 1 month before these data collection points (occasions when researchers extracted data from participants’ records). n = number of service users in the site. One participant from site 4 passed away between steps 3 & 4. One participant from site 5 was hospitalised between steps 3 & 4. Participants joined site 5 at steps 2 and 3. Problems explored are listed in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0140203#pone.0140203.t005" target="_blank">Table 5</a> and on the Profile, <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0140203#pone.0140203.s001" target="_blank">S1 appendix</a>. Fuller versions of these tables, including medians and 25^th = 75^th centiles are in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0140203#pone.0140203.s005" target="_blank">S1</a> and <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0140203#pone.0140203.s006" target="_blank">S2</a> tables.</p

Recruitment, Retention, Demographics and Prescription medicines at study entry.

<p>* Categorisation follows a needs assessment. Service users are assessed by NHS nurses and designated as needing nursing care or residential care. Assessments are usually based on the Royal College of Nursing’s (2004) ‘Nursing assessment and Older People An RCN Toolkit’. London, RCN: <a href="http://www.rcn.org.uk/__data/assets/pdf_file/0010/78616/002310.pdf" target="_blank">http://www.rcn.org.uk/__data/assets/pdf_file/0010/78616/002310.pdf</a></p><p><b>**</b> Any combination preparations were counted as a single item. Enumerating the active ingredients of each product would have been impractical, particularly for antacids and multivitamins.</p><p>Recruitment, Retention, Demographics and Prescription medicines at study entry.</p

Patient monitoring: number of participants with documentation of each problem.

<p>* Guidelines appended to the Profile offered definitions of acceptable ranges of measurement and standards. Guidelines are available on request.</p><p>2 participants joined late and 2 were lost to the study.</p

The medication chain.

<p>The medication chain.</p

Number of prescribed medicines in each step for each site.

<p>Bold text indicates roll-out of medicines’ monitoring and Profile administration 1 month before these data collection points (occasions when researchers extracted data from participants’ records). n = number of service users in the site. One participant from site 4 passed away between steps 3 & 4. One participant from site 5 was hospitalised between steps 3 & 4. Participants joined site 5 at steps 2 and 3. Problems explored are listed in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0140203#pone.0140203.t005" target="_blank">Table 5</a> and on the Profile, <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0140203#pone.0140203.s001" target="_blank">S1 Appendix</a>. Fuller versions of these tables, including medians and 25^th = 75^th centiles are in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0140203#pone.0140203.s007" target="_blank">S3 table</a>.</p

Problems addressed with and without the Profile: total numbers and examples.

<p>Visits to dentists and opticians were compared ‘before and after’ (see analysis and <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0140203#pone.0140203.t006" target="_blank">Table 6</a>). ADLs—activities of daily living.</p

Profile Effect on selected outcomes: adjusted analyses.

<p>* adjusted for Step, age, number of medicines at baseline, antipsychotics, antiepileptics, antidepressants and SSRIs at baseline;</p><p>** ICC, intracluster correlation coefficient, based on raw data;</p><p>† number of medicines recorded as prescribed at baseline.</p><p>Notes: D = raw, observed (unadjusted) difference in the same units as the variable; β = β coefficient of profile effect or effect size in the same units as variable; OR = raw (unadjusted odds ratio); aOR = adjusted Odds Ratio, exponent of β. ADL = activities of daily living. n represents the number of data collection points.</p

Numbers of participants with any change made to any of their prescribed medications at each step in each site.

<p>Bold text indicates roll-out of medicines’ monitoring and Profile administration 1 month before these data collection points (occasions when researchers extracted data from participants’ records). n = number of service users in the site. One participant from site 4 passed away between steps 3 & 4. One participant from site 5 was hospitalised between steps 3 & 4. Participants joined site 5 at steps 2 and 3. Problems explored are listed in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0140203#pone.0140203.t005" target="_blank">Table 5</a> and on the Profile, <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0140203#pone.0140203.s001" target="_blank">S1 Appendix</a>. Fuller versions of these tables, including medians and 25^th = 75^th centiles are in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0140203#pone.0140203.s007" target="_blank">S3 Table</a>.</p

Case Reports of benefits of Profile use.

<p>Case Reports of benefits of Profile use.</p